Iliac Anastomotic Stenting with a Biodegradable Poly-L-Lactide Stent: A Preliminary Study after 1 and 6 Weeks

Abstract

Purpose:

To assess the technical feasibility, thrombogenicity, and biocompatibility of a new biodegradable poly-L-lactic acid (PLLA) anastomotic stent.

Methods:

A polytetrafluoroethylene bifurcated graft was implanted in 17 pigs through a midline abdominal incision. After transverse graft incision, 17 316L stainless steel stents and 17 PLLA stents were randomly implanted at both iliac anastomotic sites and deployed with a 6-mm balloon under direct vision without angiography. Intended follow-up was 1 week in 6 pigs receiving oral acetylsalicylic acid (ASA) and in 7 pigs receiving ASA/clopidogrel; 4 pigs receiving ASA/clopidogrel were followed for 6 weeks. At the end of the study, the segments containing the stents were surgically explanted and processed for histology to measure the mean luminal diameter, intimal thickness, and the vascular injury and inflammation scores.

Results:

Initial technical success of stent placement was achieved in all animals without rupture of the suture. Two pigs died (unrelated to the stent) at 3 days after operation (1 in groups A and B). At 1 week, all PLLA stents showed thrombotic occlusion with the use of ASA alone. In contrast, all PLLA stents remained patent with concurrent administration of ASA/clopidogrel. All metal stents were patent regardless of the antiplatelet regimen. The mean luminal diameter of patent PLLA stents (4.13±0.17 mm) was comparable to metal stents (4.27±0.35 mm, p=0.78) at 1 week, but significantly diminished at 6 weeks (3.21±0.44 versus 4.19±0.18 mm, p=0.005). Histological analysis showed no signs of excessive recoil. PLLA stents induced a higher inflammation score (1.79±0.56) and more intimal hyperplasia (0.34±0.11 mm) compared to metal stents [1.27±0.44 mm (p<0.001) and 0.18±0.04 mm (p=0.006), respectively] at 6 weeks. Vascular injury was comparable between PLLA and metal stents.

Conclusion:

Biodegradable PLLA stents showed higher thrombogenicity and reduced patency compared to metal stents during early follow-up. Although ASA and clopidogrel prevented thrombotic occlusion, the increased inflammatory response and neointima formation remain major concerns of PLLA stents. A solution to this problem might be the incorporation of anti-inflammatory drugs into the PLLA stent.

Keywords

experimental study porcine model anastomotic stent poly-L-lactic acid stent thrombogenicity antiplatelet therapy aspirin clopidogrel

Get full access to this article

View all access options for this article.

References

Gray

Sullivan

Childs

. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg. 1997; 25: 74–83.

Kornowski

Hong

Tio

. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998; 31: 224–230.

Sullivan

Ainsworth

Langan

. Effect of endovascular stent strut geometry on vascular injury, myointimal hyperplasia, and restenosis. J Vasc Surg. 2002; 36: 143–149.

van der Giessen

Lincoff

Schwartz

. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996; 94: 1690–1697.

Schellhammer

Berlis

Bloss

. Polylactic-acid coating for endovascular stents. Preliminary results in canine experimental arteriovenous fistulae. Invest Radiol. 1997; 32: 180–186.

Chao

Landau

. Expandable bioresorbable endovascular stent. I. Fabrication and properties. Ann Biomed Eng. 2003; 31: 667–677.

Uurto

Juuti

Parkkinen

. Biodegradable self-expanding poly-L/D-lactic acid vascular stent: A pilot study in canine and porcine iliac arteries. J Endovasc Ther. 2004; 11: 712–718.

Vogt

Stein

Rettemeier

. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J. 2004; 25: 1330–1340.

Tamai

Igaki

Kyo

. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation. 2000; 102: 399–404.

10.

Furman

Frelinger

Michelson

. Anti-thrombotic therapy in the cardiac catheterization laboratory: Focus on antiplatelet agents. Curr Cardiol Rep. 2000; 2: 386–394.

11.

Schomig

Neumann

Kastrati

. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334: 1084–1089.

12.

Grabow

Schlun

Sternberg

. Mechanical properties of laser cut poly(L-lactide) micro-specimens: Implications for stent design, manufacture, and sterilization. J Biomech Eng. 2005; 127: 25–31.

13.

Schwartz

Huber

Murphy

. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol. 1992; 19: 267–274.

14.

Inoue

Sohma

Miyazaki

. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol. 2000; 86: 1057–1062.

15.

Kolarov

Tschoepe

Nieuwenhuis

. PTCA: Periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS). Eur Heart J. 1996; 17: 1216–1222.

16.

Uurto

Mikkonen

Parkkinen

. Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: An experimental pilot study. J Endovasc Ther. 2005; 12: 371–379.

17.

Hietala

Maasilta

Valimaa

. Platelet responses and coagulation activation on polylactide and heparin-polycaprolactone-L-lactide-coated polylactide stent struts. J Biomed Mater Res A. 2003; 67: 785–791.

18.

Tanguay

Zidar

Phillips

. Current status of biodegradable stents. Cardiol Clin. 1994; 12: 699–713.

19.

Kaul

Makkar

Nakamura

. Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study. Circulation. 1996; 94: 2228–2234.

20.

Hofma

Whelan

van Beusekom

. Increasing arterial wall injury after long-term implantation of two types of stent in a porcine coronary model. Eur Heart J. 1998; 19: 601–609.

21.

Moussa

Oetgen

Roubin

. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation. 1999; 99: 2364–2366.

22.

Harker

Boissel

Pilgrim

. Comparative safety and tolerability of clopidogrel and aspirin: Results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf. 1999; 21: 325–335.

23.

Leon

Baim

Popma

. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998; 339: 1665–1671.

24.

Samama

Bonnin

Bonneau

. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost. 1992; 68: 500–505.

25.

A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348: 1329–1339.

26.

Herbert

Tissinier

Defreyn

. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb. 1993; 13: 1171–1179.

27.

Chalmers

Hoballah

Sharp

. Effect of an endovascular stent on healing of an end-to-end polytetrafluoroethylene-artery anastomosis in a canine model. Br J Surg. 1994; 81: 1443–1447.

28.

Ohki

Marin

Veith

. Anastomotic intimal hyperplasia: A comparison between conventional and endovascular stent-graft techniques. J Surg Res. 1997; 69: 255–267.

29.

Worsey

Laborde

Miller

. Endovascular canine anastomotic stenting. J Surg Res. 1993; 54: 29–33.

30.

Ameli

Provan

Williamson

. Etiology and management of aorto-femoral bypass graft failure. J Cardiovasc Surg (Torino). 1987; 28: 695–700.

31.

LoGerfo

Quist

Nowak

. Downstream anastomotic hyperplasia. A mechanism of failure in Dacron arterial grafts. Ann Surg. 1983; 197: 479–483.

32.

Cantelmo

Quist

Lo Gerfo

. Quantitative analysis of anastomotic intimal hyperplasia in paired Dacron and PTFE grafts. J Cardiovasc Surg (Torino). 1989; 30: 910–915.